Viewing nowCombinationJBica Tablet 5/20mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Bivorzon Pharmaceutical Co., Ltd.

MFDS item code 201404716 · Approved 2014.10.15 · Insurance code 658202670
Treatment of essential hypertension not controlled with monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not sufficiently controlled with monotherapy of amlodipine or olmesartan medoxomil. It effectively lowers blood pressure, helping to prevent cardiovascular complications. It plays an important role in hypertension management and contributes to the improvement of the patient's health status.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 mg. Since the maximum blood pressure-lowering effect occurs within 2 weeks after administration, adjust the dose at intervals of 2 weeks or more, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this drug is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This drug should not be administered to patients with severe hepatic impairment. (See section 2, “Patients who should not receive this drug,” under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. Blood pressure should be monitored closely and more frequently in elderly patients.
○ Pediatric patients: The safety and efficacy of this drug have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; thus, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this drug's main ingredients or similar substances, pregnant or breastfeeding women, those with severe liver dysfunction, severe aortic stenosis, bile duct obstruction, patients undergoing renal dialysis, patients in shock, certain diabetic patients, and those with moderate to severe renal dysfunction should not use this medication. Patients with fluid or salt deficiency should be closely monitored during the initial phase of treatment, as blood pressure may drop sharply; if hypotension occurs, maintaining proper posture and, if necessary, fluid therapy may be required. Due to its vasodilatory effects, acute hypotension may rarely occur, so special caution is necessary for patients with severe aortic stenosis, obstructive coronary artery disease, or congestive heart failure. In patients with impaired kidney function, this medication may affect kidney function and kidney function should be regularly monitored, and severely impaired liver function should also be used with caution. During treatment, various side effects such as dizziness, headache, hypotension, orthostatic hypotension, edema, dyspepsia, skin rash, etc., may occur; if any abnormal symptoms arise, patients should consult medical professionals immediately. Sudden discontinuation of beta-blockers can increase risks, so while this medication is not a beta-blocker, it is essential to taper the dosage gradually when discontinuing a beta-blocker. This medication may lead to elevated blood potassium levels when taken with other antihypertensives, potassium-sparing diuretics, or potassium supplements, hence regular blood tests are necessary. This medication should not be used during pregnancy; if pregnancy is planned or confirmed, medical professionals should be informed immediately. Breastfeeding women should consider discontinuing breastfeeding or this medication as it can be transmitted through breast milk. Safety and efficacy have not been established for children under 18 years, so the use of this medication is not recommended for them. Elderly patients may have diminished kidney and liver function; thus, starting with a lower dose and adjusting the dosage carefully is advised. In case of overdose, symptoms such as severe hypotension, vasodilation, tachycardia, etc. may occur, necessitating immediate emergency treatment with close monitoring of blood pressure and heart function. Store in a closed container to prevent air and moisture from entering, and keep at room temperature between 1 to 30 degrees Celsius. This will help maintain the medication's effectiveness and prevent degradation.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to avoid exposure to air or moisture, keeping it at room temperature between 1 and 30 degrees Celsius. Proper storage ensures that the medication's efficacy is maintained and prevents degradation.
White round film-coated tablet
30 tablets (10 tablets/Alu-Alu*3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Bivorzon Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.